SUPPLEMENTARY MATERIAL For the article · 2017-03-07 · SUPPLEMENTARY MATERIAL . For the article:...
Transcript of SUPPLEMENTARY MATERIAL For the article · 2017-03-07 · SUPPLEMENTARY MATERIAL . For the article:...
![Page 1: SUPPLEMENTARY MATERIAL For the article · 2017-03-07 · SUPPLEMENTARY MATERIAL . For the article: Molecular requirements involving . the . human platelet protease-activated receptor-4](https://reader033.fdocuments.us/reader033/viewer/2022041901/5e60c42004706c2f283ed110/html5/thumbnails/1.jpg)
SUPPLEMENTARY MATERIAL
For the article:
Molecular requirements involving the human platelet protease-
activated receptor-4 mechanism of activation by peptide
analogues of its tethered-ligand
By Moschonas et al.
![Page 2: SUPPLEMENTARY MATERIAL For the article · 2017-03-07 · SUPPLEMENTARY MATERIAL . For the article: Molecular requirements involving . the . human platelet protease-activated receptor-4](https://reader033.fdocuments.us/reader033/viewer/2022041901/5e60c42004706c2f283ed110/html5/thumbnails/2.jpg)
Figure S1. A. Sequence alignment between PAR-1 and PAR-4 as predicted using Prime (in
red are shown the conserved residues); B. Ramachandran plot for the resulting homology
model (favorable region is shown in green, allowed region in blue and disallowed region in
red);
![Page 3: SUPPLEMENTARY MATERIAL For the article · 2017-03-07 · SUPPLEMENTARY MATERIAL . For the article: Molecular requirements involving . the . human platelet protease-activated receptor-4](https://reader033.fdocuments.us/reader033/viewer/2022041901/5e60c42004706c2f283ed110/html5/thumbnails/3.jpg)
Figure S2. Predicted cavities as possible binding sites in PAR-4 revealed using SiteID.
![Page 4: SUPPLEMENTARY MATERIAL For the article · 2017-03-07 · SUPPLEMENTARY MATERIAL . For the article: Molecular requirements involving . the . human platelet protease-activated receptor-4](https://reader033.fdocuments.us/reader033/viewer/2022041901/5e60c42004706c2f283ed110/html5/thumbnails/4.jpg)
Figure S3: Three-dimensional and two-dimensional docking pose of the Ac-AYPGKF-NH2
peptide in the PAR-4 structure.
![Page 5: SUPPLEMENTARY MATERIAL For the article · 2017-03-07 · SUPPLEMENTARY MATERIAL . For the article: Molecular requirements involving . the . human platelet protease-activated receptor-4](https://reader033.fdocuments.us/reader033/viewer/2022041901/5e60c42004706c2f283ed110/html5/thumbnails/5.jpg)
Figure S4: Three-dimensional and two-dimensional docking pose of the trans-cinnamoyl-
AYPGKF-NH2 peptide in the PAR-4 structure.
![Page 6: SUPPLEMENTARY MATERIAL For the article · 2017-03-07 · SUPPLEMENTARY MATERIAL . For the article: Molecular requirements involving . the . human platelet protease-activated receptor-4](https://reader033.fdocuments.us/reader033/viewer/2022041901/5e60c42004706c2f283ed110/html5/thumbnails/6.jpg)
Figure S5: Three-dimensional and two-dimensional docking pose of the YPGKF-NH2
peptide in the PAR-4 structure.
![Page 7: SUPPLEMENTARY MATERIAL For the article · 2017-03-07 · SUPPLEMENTARY MATERIAL . For the article: Molecular requirements involving . the . human platelet protease-activated receptor-4](https://reader033.fdocuments.us/reader033/viewer/2022041901/5e60c42004706c2f283ed110/html5/thumbnails/7.jpg)
Figure S6: Three-dimensional and two-dimensional docking pose of the Ac-YPGKF-NH2
peptide in the PAR-4 structure.
![Page 8: SUPPLEMENTARY MATERIAL For the article · 2017-03-07 · SUPPLEMENTARY MATERIAL . For the article: Molecular requirements involving . the . human platelet protease-activated receptor-4](https://reader033.fdocuments.us/reader033/viewer/2022041901/5e60c42004706c2f283ed110/html5/thumbnails/8.jpg)
Figure S7: Three-dimensional and two-dimensional docking pose of the caffeoyl-YPGKF-
NH2 peptide in the PAR-4 structure.
![Page 9: SUPPLEMENTARY MATERIAL For the article · 2017-03-07 · SUPPLEMENTARY MATERIAL . For the article: Molecular requirements involving . the . human platelet protease-activated receptor-4](https://reader033.fdocuments.us/reader033/viewer/2022041901/5e60c42004706c2f283ed110/html5/thumbnails/9.jpg)
Figure S8: Three-dimensional and two-dimensional docking pose of YD-3 in the PAR4
structure.
![Page 10: SUPPLEMENTARY MATERIAL For the article · 2017-03-07 · SUPPLEMENTARY MATERIAL . For the article: Molecular requirements involving . the . human platelet protease-activated receptor-4](https://reader033.fdocuments.us/reader033/viewer/2022041901/5e60c42004706c2f283ed110/html5/thumbnails/10.jpg)
Figure S9: Three-dimensional and two-dimensional docking pose of ML-354 in the PAR-4
structure.
![Page 11: SUPPLEMENTARY MATERIAL For the article · 2017-03-07 · SUPPLEMENTARY MATERIAL . For the article: Molecular requirements involving . the . human platelet protease-activated receptor-4](https://reader033.fdocuments.us/reader033/viewer/2022041901/5e60c42004706c2f283ed110/html5/thumbnails/11.jpg)
Figure S10: Three-dimensional and two-dimensional docking pose of BMS-986120 in the
PAR-4 structure.
![Page 12: SUPPLEMENTARY MATERIAL For the article · 2017-03-07 · SUPPLEMENTARY MATERIAL . For the article: Molecular requirements involving . the . human platelet protease-activated receptor-4](https://reader033.fdocuments.us/reader033/viewer/2022041901/5e60c42004706c2f283ed110/html5/thumbnails/12.jpg)
Figure S11: Superposition of the docking poses of the three small molecules [A. YD-3; B.
ML-354; C. BMS-986120 (shown in purple)] that act as antagonists for PAR-4 and the
docking pose of trans-cinnamoyl-YPGKF-NH2 (shown in green). The most important
residues involved in the binding of both the peptide and the small molecules are shown in
gray color.